NASDAQ · Biotechnology

Jasper Therapeutics, Inc. (JSPR) Stock

$0.57 +1.82% NASDAQ: JSPR Healthcare

Valuation

MetricValue
Price$0.57
Market Cap$9.27M
P/E Ratio-0.36
P/B Ratio11.48
P/S Ratio0.00
EPS (TTM)$-3.95
52-Week High$2.69
52-Week Low$0.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-618.87%
ROA-269.20%
ROCE-352.17%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.19
Current Ratio2.69

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-37.0M$-51.0M$-69.0M$-76.0M$-81.0M
Net Profit$-31.0M$-38.0M$-64.0M$-71.0M$-76.0M
EPS$-26.89$-10.33$-6.18$-4.89$-3.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$94.0M$48.0M$95.0M$80.0M$36.0M
Total Liabilities$24.0M$12.0M$16.0M$18.0M$32.0M
Cash$85.0M$38.0M$87.0M$72.0M$29.0M
Borrowings$3.0M$4.0M$3.0M$2.0M$1.0M

Latest News

Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight PR Newswire · Jun 24, 2026 Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now Zacks · Jun 3, 2026 Sector Update: Healthcare Stocks Fall Late Afternoon MT Newswires · Jun 1, 2026 Sector Update: Healthcare Stocks Fall in Afternoon Trading MT Newswires · Jun 1, 2026 Sector Update: Healthcare MT Newswires · Jun 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-34.0M$-46.0M$-52.0M$-63.0M$-77.0M
Investing Cash Flow$-5.0M$-1.0M$-1.0M$-1.0M$0
Financing Cash Flow$90.0M$0$-1.0M$1.0M$0
Net Cash Flow$65.0M$-46.0M$49.0M$-15.0M$-43.0M
Free Cash Flow$-36.0M$-46.0M$-52.0M$-63.0M$-77.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.07
FCF Yield-656.80%
Quick Ratio1.47
Interest Coverage0.00
Return 1Y-79.09%
Return 3Y-95.09%
Return 5Y-99.30%

Ownership

Insiders Held1.19%
Institutions Held56.57%
Institutions Float Held57.25%
Institutional HolderSharesReport Date
Velan Capital Investment Management LP2,668,3952026-03-31
Millennium Management Llc1,617,5312026-03-31
Acorn Capital Advisors, LLC 1,411,4922026-03-31
Kingdon Capital Management LLC1,352,1062026-03-31
Morgan Stanley1,333,4202026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLDBoundless Bio, Inc. $2.53 -1.94% -0.92 $56.86M 0.00%
BTAI $0.07 +0.00% -0.02 $2.28M 0.00%
CELUCelularity Inc. $1.56 +6.85% -0.51 $45.16M 0.00%
GBIOGeneration Bio Co. $5.34 +0.00% -0.87 $35.98M 0.00%
MURAMural Oncology plc $2.04 +0.00% -0.41 $35.38M 0.00%

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is led by CEO Jeetinder Singh Mahal, employs 64 people, headquartered in US, publicly traded since 2020.

Jasper Therapeutics, Inc. (JSPR) stock trades at $0.57 with a market capitalization of $9.27M. The stock is valued at a price-to-earnings (P/E) ratio of -0.36, price-to-book of 11.48, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.32 and $2.69, and currently trades 78.8% below its 52-week high.

On profitability, Jasper Therapeutics, Inc. generates a return on equity (ROE) of -618.87%, return on capital employed of -352.17%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides